Misk Pharma is dedicated to the acquisition, development, and commercialization of high-quality branded pharmaceuticals. Our portfolio includes innovative therapies in pain management, anti-infectives, cardiovascular care, and psychiatry.
With strong in-house expertise and a global network of partners, our business model ensures speed, flexibility, and a competitive edge in bringing advanced treatments to market. Through continuous innovation, we strive to improve patient outcomes and expand access to high-value medications

Misk Pharma is set to introduce a groundbreaking portfolio of pharmaceutical products, featuring the first generic versions of several high-impact therapies. This includes the introduction of generic Semaglutide—an innovative treatment for diabetes and weight management—and Ferric Carboxymaltose, a vital intravenous iron therapy. With this launch, Misk Pharma reinforces its commitment to increasing access to advanced, high-quality treatments while offering cost-effective alternatives to patients and healthcare providers alike.